

**Mr. Javier Ruiz del Pozo**  
Head of Secondary Markets  
CNMV  
Edison, 4  
28006 Madrid

Barcelona, June 12, 2015

## RELEVANT FACT

Dear Sir,

In accordance with Law 24/1988, of July 28, relative to the regulation of the stock markets and related provisions, LABORATORIO REIG JOFRE SA ("Reig Jofre" or "the Company"), formerly NATRACEUTICAL SA, informs that, the Shareholders General Meeting has been held upon the first call on June 11, 2015, with the Agenda established and 74.49% of present shareholders and 12.54% of represented shareholders, owning 87.03% of the share capital.

All resolutions were adopted by the legal and statutory majorities, in the following sense:

<b>Agenda item</b>	<b>Resolution adopted by a majority of</b>
<b>1.1</b>	87.03%
<b>1.2</b>	87.03%
<b>1.3</b>	87.03%
<b>1.4</b>	87.03%
<b>1.5</b>	87.03%
<b>1.6</b>	87.03%
<b>2</b>	87.03%
<b>3</b>	87.03%



<b>4</b>	87.03%
<b>5.1.1.1</b>	87.03%
<b>5.1.1.2</b>	87.03%
<b>5.1.1.3</b>	87.03%
<b>5.1.2.1</b>	87.03%
<b>5.1.2.2</b>	87.03%
<b>5.1.2.3</b>	87.03%
<b>5.1.3.1</b>	87.03%
<b>5.1.3.2</b>	87.03%
<b>5.1.3.3</b>	87.03%
<b>5.1.3.4</b>	87.03%
<b>5.1.3.5</b>	87.03%
<b>5.1.3.6</b>	87.01%
<b>5.1.4.1.</b>	87.03%
<b>5.1.4.2.</b>	87.03%
<b>5.1.4.3.</b>	87.03%
<b>5.1.4.4.</b>	87.03%
<b>5.1.4.5.</b>	87.03%
<b>5.1.4.6.</b>	87.03%
<b>5.1.4.7.</b>	87.03%
<b>5.1.4.8.</b>	87.03%
<b>5.1.4.9.</b>	87.03%
<b>5.1.4.10.</b>	87.03%
<b>5.1.4.11.</b>	87.03%
<b>5.1.4.12.</b>	87.03%
<b>5.1.4.13.</b>	87.03%
<b>5.2</b>	87.01%
<b>6</b>	87.03%
<b>7</b>	87.01%



<b>8</b>	87.03%
<b>9.1</b>	87.03%
<b>9.2</b>	87.03%
<b>9.3</b>	87.03%
<b>9.4</b>	87.03%
<b>10</b>	87.03%

According to the previous vote, all resolutions adopted were the following:

- I. The individual and consolidated financial statements and the individual and consolidated management reports, the allocation of results and the conduct of business of the board of directors for the year 2014 were approved.
- II. It was approved the authorization of the board of directors to carry out the derivative acquisition of treasury stock, either directly or via subsidiaries, with the limits and requirements established in the Corporations Act, thus superseding the authorization granted in the Meeting of 30 June 2014.
- III. On a consultative basis, it was approved the report on the remuneration of the directors of Reig Jofre for 2014.
- IV. It was approved the directors' remuneration policy and the remuneration of the executive directors for future years.
- V. It was approved the amendment of the bylaws in the followings chapters, as well as the consolidated text with the amendments approved:
  - Chapter I: articles 2, 3 and 4
  - Chapter II: articles 6, 9 and 10
  - Chapter IV: articles 14, 15, 19, 20, 21 and 24
  - Chapter V: articles 25, 26, 27, 28, 29, 30, 32, 33, 34, 35, 36, 36 bis and 36 ter
- VI. It was approved that, for the call of an extraordinary shareholders' meeting, the applicable term be fifteen days.
- VII. It was approved the amendment of the General Shareholders Meeting Regulations.



VIII. It was approved the reverse split and cancellation of 1,264,284 currently outstanding shares, for their exchange for new shares to be issued at a ratio of one new share for every twenty existing shares.

IX. The chairman and secretary of the board of directors were granted powers for the development, documentation and implementation of the resolutions adopted by the general shareholders' meeting.

The presentation of the Shareholders' meeting is available on the Spanish version of Reig Jofre's website [www.reigjofre.com](http://www.reigjofre.com) section "Information for Shareholders and Investors - Shareholders General Meeting".

Yours faithfully,

Adolf Rousaud  
Secretary of the Board of Directors  
Laboratorio Reig Jofre SA